Pathfinder Cell Therapy, Inc. (OTCPK: PFND)
Health Care · Biotechnology · US
$—
— today · — 1Y
Pathfinder Cell Therapy, Inc. (OTCPK: PFND) operates in the Biotechnology industry within the Health Care sector. The company is valued at $667.00 and employs 1 people.
trading between 0.00 and 0.00.
Tweenvest scores Pathfinder Cell Therapy, Inc. across four factors: quality 6/100. Its strongest factor is quality.
PFND price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $667.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -29.22
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 667.16M
- Employees
- 1
- Next earnings
- —
About Pathfinder Cell Therapy, Inc.
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
- ISIN
- US70319A1060
- Founded
- 2008
- Listed since
- Jan 3, 2000
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.40 | -1.28% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.34 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.27 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.09 | -0.50% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $824.00 | -1.15% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.54 | -5.85% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.